Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Catheterization Laboratories, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Int J Cardiol. 2021 Mar 15;327:45-51. doi: 10.1016/j.ijcard.2020.11.035. Epub 2020 Nov 21.
Background Immediate and long-term functional outcomes after percutaneous treatment of small vessel disease (SVD) with drug-coated balloon (DCB) versus drug-eluting stent (DES) remain unknown. The study sought to investigate whether treatment of de novo SVD with DCB yields similar functional results compared with DES, as judged with angiography-based quantitative flow ratio (QFR). Methods and results QFR was measured at pre-procedural, post-procedural and 9-month angiography in all available subjects from the non-inferiority RESTORE SVD China trial, in which patients were randomized to Restore DCB (n = 116) or Resolute DES (n = 114) study arms. Primary outcome of this analysis was 9-month QFR. Pre-procedural, post-procedural and 9-month QFR was performed in 84.8% (195/230), 83.0% (191/230) and 93.8% (181/193) cases, respectively. At 9 months, the QFR of DCB showed no significant difference to DES (0.88 ± 0.23 vs. 0.92 ± 0.12, p = 0.12). Both 9-month QFR and the QFR difference between post-procedure and 9-month follow-up were correlated with angiographic percentage of diameter stenosis and late loss, and predictive of 2-year clinical outcome. Conclusions Treatment of coronary SVD with DCB resulted in similar 9-month functional results compared with DES. This study provides evidences to the value of QFR as a mean of evaluating device performance after coronary revascularization. Clinical trial registration URL: https://www.clinicaltrials.gov; ClinicalTrial.gov: Identifier: NCT02946307.
经皮药物涂层球囊(DCB)与药物洗脱支架(DES)治疗小血管疾病(SVD)的即刻和长期功能结果尚不清楚。本研究旨在通过基于血管造影的定量血流比(QFR)评估,研究与 DES 相比,DCB 治疗新发 SVD 是否具有相似的功能结果。
在非劣效性 RESTORE SVD China 试验中,所有可用于分析的受试者均在术前、术后和 9 个月行 QFR 测量,该试验将患者随机分为 Restore DCB 组(n=116)和 Resolute DES 组(n=114)。该分析的主要终点为 9 个月时的 QFR。分别有 84.8%(195/230)、83.0%(191/230)和 93.8%(181/193)的病例进行了术前、术后和 9 个月时的 QFR 检查。9 个月时,DCB 的 QFR 与 DES 无显著差异(0.88±0.23 比 0.92±0.12,p=0.12)。9 个月时的 QFR 和术后与 9 个月随访之间的 QFR 差值与血管造影直径狭窄百分比和晚期丢失相关,并可预测 2 年临床结局。
DCB 治疗冠状动脉 SVD 的 9 个月功能结果与 DES 相似。本研究为 QFR 作为评估冠状动脉血运重建后器械性能的一种手段提供了证据。
https://www.clinicaltrials.gov;ClinicalTrials.gov:标识符:NCT02946307。